Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion-Reference-Cited by-同舟云学术

Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion

Published:2022-01-01 Issue:1 Volume:4 Page:
ISSN:2632-2498
Container-title:Neuro-Oncology Advances
language:en
Short-container-title:

Author:

Kurozumi Kazuhiko¹^ORCID,Fujii Kentaro²,Washio Kana³,Ishida Joji²,Otani Yoshihiro²,Sudo Tamotsu⁴,Tahara Makoto⁵^ORCID,Ichimura Koichi⁶⁷,Ennishi Daisuke⁸,Date Isao²

Affiliation:

1. Department of Neurosurgery, Hamamatsu University School of Medicine , Shizuoka , Japan

2. Department of Neurological Surgery, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences , Okayama , Japan

3. Department of Pediatrics, Okayama University Hospital , Okayama , Japan

4. Section of Translational Research, Hyogo Cancer Center , Akashi , Japan

5. Department of Head and Neck Medical Oncology, National Cancer Center Hospital East , Kashiwa, Chiba , Japan

6. Division of Brain Tumor Translational Research, National Cancer Center Research Institute , Tokyo , Japan

7. Department of Brain Disease Translational Research, Graduate School of Medicine, Juntendo University , Tokyo , Japan

8. Center for Comprehensive Genomic Medicine, Okayama University Hospital , Okayama , Japan

Funder

Japanese Ministry of Education, Culture, Sports, Science and Technology

Publisher

Oxford University Press (OUP)

Subject

Electrical and Electronic Engineering,Building and Construction

Link

https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdac094/44045131/vdac094.pdf

Reference10 articles.

1. High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene;Kurozumi;Brain Tumor Pathol.,2019

2. FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors;Marcus;Clin Cancer Res.,2021

3. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors;Doz;Neuro Oncol.,2022

4. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors;Demetri;Clin Cancer Res.,2022

5. Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy;Chu;Future Oncol.,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic medicine advances for brain tumors;International Journal of Clinical Oncology;2024-05-10

2. Entrectinib/temozolomide;Reactions Weekly;2023-12-09

3. Entrectinib treatment induces a durable response against ARHGEF11::NTRK1 fusion gene‐positive spinal cord diffuse pediatric‐type high‐grade glioma;Pediatric Blood & Cancer;2023-07

4. Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas;Brain Tumor Pathology;2023-04

5. NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series;Journal of Personalized Medicine;2022-11-02